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Abstract
Background The purpose of this study was to examine the
effect of aldosterone receptor blockade on the
immunopathogenesis and progression of nephritis in the (NZB
× NZW) F1 murine lupus model.
Methods Female NZB/W F1 mice (11 weeks old) were treated
daily with 25 or 50 mg/kg oral spironolactone or vehicle.
Proteinuria, renal function, and serum autoantibody levels were
monitored. Renal histopathology, immune complex deposition,
and immunohistochemistry were analyzed at various time points.
Targeted microarray analysis was performed on renal tissue,
with subsequent real-time PCR analysis of several differentially
expressed genes.
Results Treatment with spironolactone was well tolerated by
the mice throughout the course of their disease progression,
with no significant differences in azotemia or serum potassium
levels between vehicle-treated and spironolactone-treated
animals. By 36 weeks of age, fewer spironolactone-treated mice
developed nephrotic range proteinuria as compared with the
control mice (control 70.8%, 25 mg/kg spironolactone 51.3%,
and 50 mg/kg spironolactone 48.6%). Compared with control
mice, mice treated with 25 mg/kg spironolactone had
significantly lower serum anti-single-stranded DNA levels (2,042
μg/ml versus 1,036 μg/ml; P = 0.03) and anti-double-stranded
DNA levels (3,433 μg/ml versus 614 μg/ml; P = 0.05).
Spironolactone-treated mice exhibited decreased
histopathologic evidence of inflammation and tissue damage, as
compared with control mice. Additionally, spironolactone
treatment resulted in decreased expression in the kidney of
several inflammatory and proapoptotic genes, including those
encoding interferon-γ, B lymphocyte stimulator (BlyS), tumor
necrosis factor related apoptosis inducing ligand (TRAIL), tumor
necrosis factor related weak inducer of apoptosis (TWEAK),
and Fas ligand.
Conclusion Aldosterone receptor blockade is safe and well
tolerated in progressive murine lupus nephritis, and it results in
decreased levels of clinical proteinuria, lower serum levels of
autoantibodies, and decreased kidney damage. It appears to
modulate inflammatory changes during the progression of
glomerulonephritis and may also have a previously undescribed
role in attenuating apoptosis.
Introduction
Renal involvement is a major cause of morbidity and mortality
in systemic lupus erythematosus (SLE). The underlying patho-
genesis of the diverse clinical and histopathologic manifesta-
tions of lupus nephritis is still not well understood, although a
complex interplay of genetic factors, autoantibodies (auto-
Abs), inflammatory responses, and aberrant apoptosis has
been implicated [1]. Lupus nephritis is often referred to as the
prototypic immune complex (IC) disease, in which glomerular
deposition of circulating ICs or in situ formation of renal
autoantigen-autoAb complexes results in the recruitment of
inflammatory cells, cytokine and vasoactive substance release,
and complement activation [2]. In addition to inflammatory
nephritis, lupus renal involvement can also manifest as a
fibrotic, atrophic nephropathy with significant renal functional
impairment and potential progression to end-stage disease.
Although this manifestation can be the progressive result of
earlier unchecked inflammation, this may not always be the
case, and the precise relationship between acute inflammatory
and chronic fibrotic nephropathy is unclear [3-5]. Thus,
therapeutics focusing solely on suppression of inflammation
may be inadequate in preventing terminal fibrotic damage.Page 1 of 9
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static regulator of renal function, has long been known to par-
ticipate in the pathogenesis of renal disease [6,7], although
the specific role played by aldosterone in chronic renal dis-
ease has only recently received attention [8,9]. In addition to
the hemodynamic effects of sodium retention and systemic
vasoconstriction, aldosterone has a number of well docu-
mented profibrotic effects. It can promote fibrosis in target
organs via direct effects on vascular smooth muscle cells,
endothelial cells, renal fibroblasts, and mesangial cells; addi-
tionally, aldosterone modulates expression of various profi-
brotic mediators, including transforming growth factor-β1,
plasminogen activator inhibitor-1, and reactive oxygen species
(for reviews [10-12]). Aldosterone also exerts proinflammatory
effects in the kidney and other tissues [13,14], such as leuko-
cyte infiltration and increased expression of inflammatory
cytokines. In addition, aldosterone can generate cytosolic cat-
ion imbalances in mononuclear cells, resulting in an immunos-
timulatory phenotype [15]. These findings suggest an
intriguing potential immunomodulatory role for aldosterone,
which could be important in the pathogenesis and progression
of lupus nephritis.
A number of diverse animal models of renal dysfunction have
demonstrated that aldosterone blockade attenuates proteinu-
ria and histopathologic parameters of renal injury [12,16-22].
Additionally, overactivity of the renin-angiotensin axis and the
beneficial effects of angiotensin blockade in lupus nephritis
has been demonstrated [23,24]. However, the role of aldos-
terone and the effects of aldosterone blockade on lupus
nephritis specifically have not been characterized. We exam-
ined the effect of the aldosterone receptor antagonist spironol-
actone on the development and progression of nephritis in the
NZB/W F1 murine model of SLE.
Materials and methods
Animals
Female NZB/W F1 mice, aged 6 to 8 weeks, were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA) and
housed in individual cages in a specific pathogen-free barrier
facility at the University of Michigan. All experiments were
approved by the institutional committee for animal use.
Reagents
Spironolactone (Sigma, St. Louis, MO, USA) was suspended
in a vehicle of 1:1 mixture of Ora-Plus (Paddock Laboratories,
Minneapolis, MN, USA) and strawberry syrup, purchased from
the University of Michigan Hospital Stores (Ann Arbor, MI,
USA). Sugar-free gelatin (Jell-O brand) was purchased
commercially.
Spironolactone treatment and monitoring
Preliminary experiments revealed spironolactone to be insolu-
ble at our desired concentrations in nontoxic solvents. There-
fore, spironolactone suspension or vehicle alone was mixed
with gelatin at varying concentrations contained in a 1 cm3
cube of gelatin; gelatin/drug cubes were made on a daily
basis. The mice routinely ate the entire amount provided.
Eleven-week-old prenephritic mice were fed daily either
spironolactone 50 mg/kg (n = 16), spironolactone 25 mg/kg
(n = 16), or vehicle alone (n = 16; referred to as 'control'). The
doses chosen were based on those safely tolerated in other
murine nephropathy models in the literature [19,25] and are
10-fold to 20-fold higher than those routinely received by
humans (about 2.5 mg/kg per day). Randomly sampled mice
from each group were periodically weighed and tail cuff pres-
sures obtained. To monitor for hyperkalemia and uremia, mice
were bled via retro-orbital approach every 4 weeks; serum was
immediately isolated using serum separator tubes and then
frozen at -80°C until use. Serum autoAbs were measured at
baseline and at ages 25 and 36 weeks. Proteinuria was deter-
mined by collecting spot urine samples, initially every 4 weeks
and then weekly after age 25 weeks, and analyzed immediately
upon collection. At 25 weeks old, half of the mice in each
group were killed, whereas the remaining mice continued their
respective treatments and blood and urine collection until 36
weeks, at which time they were killed. Additionally, five
untreated 11 week old mice were killed at the beginning of the
protocol to determine baseline parameters.
Serum and urine measurements
Proteinuria was measured using Uristix (Bayer, Elkhart, IN,
USA) and expressed semiquantitatively: 0 (none-trace), 1+
(30 mg/dl), 2+ (100 mg/dl), 3+ (300 mg/dl), 4+ (>2000 mg/
dl). Serum potassium and blood urea nitrogen levels were
assayed using colorimetric kits (Stanbio Laboratory, Boerne,
TX, USA), as per the manufacturer's protocols. Levels of auto-
Abs against single-stranded DNA (ssDNA) and double-
stranded DNA (dsDNA) were determined by enzyme-linked
immunosorbent assay (Alpha Diagnostic, San Antonio, TX,
USA), as per the manufacturer's protocols. The detection lim-
its were 400 ng/ml and 156 ng/ml for anti-dsDNA and anti-
ssDNA antibodies, respectively.
Kidney preparation for immunohistochemistry, 
immunofluorescence, and RNA extraction
Mice were fully anesthetized with pentobarbital. The abdomen
was dissected and the abdominal aorta, inferior vena cava, kid-
neys, and renal vasculature were exposed. The aorta was can-
nulated with an angiocatheter, the inferior vena cava
punctured, and the vasculature perfused with ice cold phos-
phate-buffered saline (Invitrogen, Carlsbad, CA, USA) at a rate
of approximately 12 ml/min for 5 minutes. The left renal vascu-
lar bundle was ligated with surgical suture and the kidney
removed. A section of cortex was snap frozen in liquid nitrogen
and stored at -80°C for immunofluorescence staining; the
remaining tissue was homogenized in TriPure isolation reagent
(Roche, Indianapolis, IN) and frozen for future RNA extraction.Page 2 of 9
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ture with ice cold 4% paraformaldehyde for 10 minutes,
removed, and placed in 10% formalin for future paraffin
embedding and sectioning.
Histopathology studies
Kidneys fixed in formalin were processed, paraffin embedded,
and sectioned at 2 to 3 μm thickness. Hematoxylin and eosin
or Masson's trichrome stained sections were examined and
graded by one of the authors (PDK) in a blinded manner. A
semiquantitative scoring system (0 = no involvement, 1 = min-
imal involvement [0% to 25% of section], 2 = moderate
involvement [26% to 50% of section], and 3 = severe involve-
ment [>50% of section]) was used to assess 13 different
parameters of activity and chronicity (mesangial hypercellular-
ity, mesangial deposits, mesangial sclerosis, endocapillary cel-
lular infiltrate, subepithelial and subendothelial deposits,
capillary thrombi, capillary sclerosis, cellular or organized cres-
cents, synechiae, tubular atrophy, and interstitial fibrosis). An
activity index and a chronicity index were generated by compil-
ing scores from groups of related parameters (for activity:
mesangial hypercellularity, mesangial deposits, and endocap-
illary cellular infiltrate; for chronicity: interstitial fibrosis, tubular
atrophy, synechiae, organized crescents, and capillary
sclerosis).
Immunohistochemistry/immunofluorescence staining of 
kidney sections
Immunohistochemistry for rat anti-mouse F4/80 (Serotec,
Raleigh, NC, USA) or concentration-matched rat IgG (South-
ern Biotech, Birmingham, AL, USA) was performed on paraffin
sections using avidin-biotin complex techniques (Vectastain
Elite ABC kit, Vector Laboratories, Burlingame, CA, USA) and
visualization with diaminobenzidine. Scoring was performed in
a blinded manner, as previously described [26]. Immunofluo-
rescence staining was performed as described previously [27]
using FITC goat anti-mouse C3 (Cappel Laboratories, Mal-
vern, PA, USA) and Alexa Fluor 594 F(ab')2 goat anti-mouse
IgG (Invitrogen). Glomerular staining was graded according to
intensity on a 0 to 4+ scale (0 = no staining; 4+ = maximum
intensity staining).
RNA analysis
Renal RNA was extracted using TriPure as per the manufac-
turer's protocol and further purified using an RNEasy Mini Kit
(Qiagen Inc., Valencia, CA, USA). RNA was pooled from mice
within the same age and treatment group. Targeted microar-
rays (Superarray, Frederick, MD, USA) looking at inflammatory
cytokine (MM-003) and extracellular matrix-related genes
(OMM-013) were performed as per the manufacturer's proto-
col; gene expression relative to age-matched, vehicle-treated
control animals was determined using the manufacturer's soft-
ware, corrected for background and normalized to the median.
The data discussed in this report have been deposited in
National Center for Biotechnology Information's Gene Expres-
sion Omnibus (GEO) [28] and are accessible through GEO
Series accession number GSE10144. Pooled RNA was fro-
zen at -80°C before use in real-time PCR.
Real-time PCR
cDNA was generated using Superscript 2 (Invitrogen), reverse
transcriptase, and random hexamers. The primers used are
summarized in Table 1. Real-time PCR was carried out in trip-
licate on an Applied Biosystems 7900 HT sequence detection
system using SYBR green master mix (Applied Biosystems,
Foster City, CA, USA), optimized concentrations of forward
and reverse primers, and 25 ng cDNA. PCR conditions were
as follows: one cycle of 95°C for 4 minutes, then 40 cycles of
95°C for 15 seconds and 60°C for 1 minute. Fold induction/
repression was determined using the 2-ΔΔCt relative quantifica-
tion method, normalized against GAPDH (glyceraldehyde 3-
phosphate dehydrogenase).
Statistics
Kaplan-Meier plots for survival and proteinuria were compared
using nonparametric log-rank testing. Serum chemistry and
autoantibody levels were compared using Student's t-test.
Renal histopathology scores were analyzed using nonpara-
metric Kruskall-Wallis testing.
Results
Clinical effects of spironolactone treatment
There were no significant differences between mice in differ-
ent treatment groups with regard to survival, weight, blood
pressure, serum urea nitrogen, or serum potassium levels at




IFN-γ Forward: 5'-CAT TGA AAG CCT AGA AAG TCT GAA 
TAA C-3'
Reverse: 5'-TGG CTC TGC AGG ATT TTC ATG-3'
BlyS Forward: 5'-CAG GAA CAG ACG CGC GAT TTC-3'
Reverse: 5'-GTT GAG AAT GGC GGC ATC C-3'
TRAIL Forward: 5'-GAT CAC TCG GAG AAG CAA CTC A-3'
Reverse: 5'-GAG AGG ACT CCC AGG ATT CAA TG-3'
TWEAK Forward: 5'-CGA GCT ATT GCA GCC CAT TAT-3'
Reverse: 5'-ACC TGC TTG TGC TCC ATC CT-3'
FasL Forward: 5'-GCA CAT AGC CAA CCC CAG TAC AC-3'
Reverse: 5'-GCC ACC TTT ATT ATA CTT CAC TCC 
AG-3'
BlyS, B lymphocyte stimulator; FasL, Fas ligand; IFN, interferon; 
TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; 
TWEAK, tumor necrosis factor-like weak inducer of apoptosis.Page 3 of 9
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Mice were tested initially on a biweekly and then weekly basis
for proteinuria. In general, mice began to exhibit sustained low-
grade proteinuria at around 20 weeks of age. We determined
the time to onset of nephrotic range proteinuria, defined as a
spot urine analysis of 3+ (300 mg/dl) or greater, sustained for
2 weeks or more. Although there were no statistically signifi-
cant differences between the three groups over the entire
course of the study in development of nephrotic range pro-
teinuria, by age 36 weeks fewer spironolactone-treated mice
had developed nephrotic range proteinuria compared with the
control mice (control 70.8%, 25 mg/kg spironolactone 51.3%,
50 mg/kg spironolactone 48.6%; P = 0.331 comparing con-
trol with spironolactone 50 mg/kg; Figure 1).
Effects of spironolactone on serum autoantibodies
Serum levels of autoAbs were determined at baseline, age 25
weeks, and age 36 weeks from randomly sampled mice in
each treatment group. There were significant differences in
anti-ssDNA antibody levels (Figure 2a) between control mice
and mice treated with 25 mg/kg per day spironolactone by 36
weeks of age (mean level: control 2,042 ± 356 μg/ml, treated
1,036 ± 225 μg/ml; P = 0.02), whereas no significant differ-
ences between control mice and mice treated with 50 mg/kg
per day spironolactone (mean: 1,628 ± 381 μg/ml; P = 0.40)
were observed. Additionally, there were significant differences
in anti-dsDNA antibody levels (Figure 2b) between the control
and 25 mg/kg per day spironolactone groups (mean: control
3,433 ± 1,370 μg/ml, treated 614 ± 336 μg/ml; P = 0.05) but
not the 50 mg/kg per day spironolactone group (mean 2,890
± 1,569 μg/ml; P = 0.78).
Effects of spironolactone on renal histopathology, 
immune complex deposition, and macrophage 
infiltration
On histopathologic analysis of hematoxylin and eosin stained
and trichrome stained kidney sections, there were marked dif-
ferences between treated and control mouse kidneys, most
pronounced by 36 weeks of age (Figure 3). The kidneys of
control mice at 36 weeks exhibited typical features of severe
glomerulonephritis, with enlarged glomeruli, mesangial expan-
sion, hypercellularity and deposits, thickened capillary loops
with subepithelial deposits, and crescents (Figure 3a,c). The
Figure 1
Effect of spironolactone on the development of nephrotic range proteinuria pro-
teinuria. The age at onset of nephrotic range proteinuria was compared 
between treatment groups. At the 36-week time point, 70.8% of the 
control mice had nephrotic proteinuria (as opposed to 51.3% and 
48.6% of the mice treated with 25 mg/kg per day and 50 mg/kg per 
day, respectively). Sixteen animals were included in each group at the 
start of the study. P = 0.331, control versus spironolactone 50 mg/kg 
per day.
Figure 2
Effect of spironolactone on autoantibody levelsl l . At 36 weeks of age, there were significant differences in (a) anti-single-stranded DNA (ssDNA) and 
(b) anti-double-stranded DNA (dsDNA) antibody levels between control mice and mice treated with 25 mg/kg per day spironolactone. Results rep-
resent the mean ± standard error in six to eight mice/group. *P = 0.02, **P = 0.05.Page 4 of 9
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exhibited less severe glomerulonephritis, with no crescents
observed as well as diminished overall cellularity, whereas the
capillary loops and mesangium contained less prominent
deposits (Figure 3b,d).
To quantitate histologic differences, a semiquantitative scor-
ing system from 0 to 3 was used to grade 13 different histo-
logic parameters of activity and chronicity. Half of the control
mice had cellular crescents present by 36 weeks, whereas
none of the treated mice had any (Figure 4a; P = 0.05). In most
of the other individual parameters assessed (Figure 4b, repre-
sentative) there was also less prominent disease in treated
versus control mice. To assess for relative differences more
globally, individual parameters were combined to generate
activity (mesangial hypercellularity, mesangial deposits, and
endocapillary cellular infiltrate) and chronicity (interstitial
fibrosis, tubular atrophy, synechiae, organized crescents, and
capillary sclerosis) scores. Again, less histopathologic global
activity was observed in treated versus control mice (Figure
4c; P = 0.10), with less prominent differences in chronicity
scores between treatment groups (Figure 4d).
To determine whether spironolactone treatment resulted in
obvious differences in glomerular IC deposition, indirect
immunofluorescence staining for IgG and C3 was performed
and scored in a blinded manner at 25 weeks of age, which is
in the age range when initial florid immune complex deposition
occurs [29]. No differences were detected between treated
and control mice, despite intense staining for both IgG and C3
in two-thirds of all animals. Additionally, immunohistochemical
staining for F4/80 to evaluate for macrophage infiltration was
performed, and no significant differences between treatment
groups were observed (data not shown). We did not evaluate
IC deposition at 36 weeks, because – as we previously
reported [27] – it is difficult to detect significant differences in
the amount of renal ICs at this later course of the disease,
when end-stage has occurred in lupus-prone mice and maxi-
mum IC deposition has taken place.
Gene expression changes with spironolactone
RNA harvested from whole renal tissue was used to perform
targeted microarrays, evaluating changes in the expression of
approximately 150 cytokine and extracellular matrix-related
genes. We found that B lymphocyte stimulator (BLyS) was
readily detectable in NZB/W kidneys at age 11 weeks, well
before clinical disease manifestations were apparent. Surpris-
ingly, we found no differences in the expression of transform-
ing growth factor-β or other fibrosis-associated genes in our
microarray screen at any of our examined time points. We also
Figure 3
The effect of spironolactone on renal histopathology. Representative light photomicrographs of Masson trichome stained sections from kidneys of 
(a,c) control and (b,d) 50 mg/kg per day spironolactone treated mice are shown. All of the mice exhibited evidence of proteinaceous, fuchsinophilic 
deposits in the subepithelial space with thickening of the capillary loops. The mesangium was also expanded in both groups but the cellularity was 
more commonly increased in the control animals (thin yellow arrow). In addition, the control mice had an active glomerulonephritis with prominent 
proliferation of extraglomerular cells forming crescents that have begun to organize (thick yellow arrows). Subendothelial deposits and hyaline 
thrombi were also much more commonly encountered in the control animals. Original magnification: 420× for panels a and b, and 840× for panels c 
and d.Page 5 of 9
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result of spironolactone treatment. However, we did find differ-
ential expression of a number of genes between treated and
control mice, and, based on these semiquantitative results,
real-time reverse transcription PCR was performed on
selected genes that exhibited consistent changes in expres-
sion by spironolactone by microarray analysis and were of
potential pathogenic interest. By 36 weeks of age, spironolac-
tone treatment resulted in decreased renal expression (by real-
time reverse transcription PCR) of several inflammatory and
proapoptotic genes, which was most marked in the 25 mg/kg
per day treatment group. Specifically, the fold changes in
expression detected in the 25 mg/kg per day treatment group
relative to age-matched control mice were as follows: 0.65 for
IFN-γ; 0.52 for BlyS; 0.58 for tumor necrosis factor-like weak
inducer of apoptosis (TWEAK); 0.70 for tumor necrosis factor
related apoptosis-inducing ligand (TRAIL); and 0.49 for Fas
ligand.
Discussion
Treatment of lupus nephritis utilizes immunosuppressives that
predominantly target cell-mediated immunity. Because of their
potency and nonspecificity, these agents have a variety of
undesirable side effects. Additionally, treatment with cytotoxic
agents alone may not adequately ameliorate other processes
that are involved in progression of kidney disease, which is the
Figure 4
Semiquantitative scoring of histological spironolactone effects. Thirteen renal histopathological parameters were blindly scored from 0 (unaffected) 
to 3 (severely affected): (a) cellular crescent score, (b) mesangial cellularity score, (c) activity score, and (d) chronicity score. At 36 weeks, there 
were significant differences in cellular crescent formation between treated and control mice (panel a; *P = 0.05) and better scores in treated mice in 
most other parameters (representative in panel b). A combined score revealed treated mice to have a better activity index (panel c; P = 0.10). Chro-
nicity indices were similar compared with control mice (panel D). Data are presented as the percentage of mice in each treatment group that had the 
indicated score; each treatment group included seven or eight mice by the 36-week time point.Page 6 of 9
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tis. Thus, adjunctive medication regimens must be developed.
Aldosterone is an attractive therapeutic target, given our cur-
rent understanding of the pathophysiology of lupus nephritis
and the clinical utilization of aldosterone blockade in other dis-
eases. We undertook this study to characterize better the
effects of aldosterone receptor blockade on different compo-
nents of progressive murine lupus glomerulonephritis, as proof
of concept prior to analyzing ultimately its utility as an adjunc-
tive therapy.
Utilizing the NZB/W F1 model, which closely resembles human
SLE [29], we found no differences in blood pressure between
spironolactone-treated and control mice, which suggests that
effects from systemic hypoperfusion were unlikely. Spironolac-
tone did not accelerate the progression of uremia, as indicated
by serum blood urea nitrogen levels, which suggests that local
renal hemodynamic effects were not detrimental. Hyperkale-
mia is a well documented consequence of aldosterone block-
ade, especially in renal insufficiency, and can be a cause of
morbidity/mortality [30]. However, serum potassium levels
were similar in treated and control mice, despite progressive
glomerulonephritis and worsening renal function. Thus,
spironolactone could safely be administered on a chronic
basis in a model of progressive glomerulonephritis and renal
impairment.
The presence of nephrotic range proteinuria indicates signifi-
cant, although not necessarily irreversible, glomerular damage.
In this proof of concept study, we observed a modest but
consistently diminished incidence of nephrotic range proteinu-
ria in spironolactone-treated mice. By the final 36-week time
point, the treatment groups appeared to be diverging. Prolon-
gation of the study beyond 36 weeks may potentially have
resulted in a sustained increase in the incidence of proteinuria
in control compared with treated mice. It is also feasible,
however, that if spironolactone exerts most of its effects early
in the development of glomerulonephritis, then no further dim-
inution in proteinuria onset would be observed at later time
points; follow-up studies are needed to address this.
DNA autoAbs, especially to dsDNA, are detected in a subset
of patients with SLE, are highly lupus specific, and are
pathogenic in lupus nephritis [31-33]. By 36 weeks of age,
mice in the 25 mg/kg per day treatment group had significantly
lower serum levels of both anti-ssDNA and anti-dsDNA anti-
bodies compared with control mice. However, we did not
detect differences in glomerular IC deposition. Therefore,
spironolactone does appear to diminish serum levels of anti-
DNA antibodies, but this does not result in diminished renal
ICs. Potentially, deposition or in situ formation of ICs to other,
non-DNA, antigens persists and is unaffected by
spironolactone treatment. Alternatively, the degree of autoAb
diminution may be insufficient to result in clinically detectable
decreases in renal ICs. We observed statistically significant
differences in serum autoAb levels only at 36 weeks of age,
which is after renal IC deposition occurs; thus, it is possible
that spironolactone may exert effects on autoAbs that are tem-
porally irrelevant.
The most compelling changes found were in renal histology.
Treated mice consistently exhibited less severe histologic evi-
dence of glomerulonephritis compared with control mice. The
parameters that exhibited the most improvement were markers
of activity (mesangial cellular infiltrates, subepithelial deposits,
among others). Although only the presence of cellular cres-
cents was significantly different between treated and control
kidneys, scoring of other parameters was highly suggestive of
a similar trend. There were less marked differences between
treated and control mice in the presence of chronic lesions
(tubular atrophy and fibrosis, capillary sclerosis). This was sur-
prising, given that aldosterone receptor blockade is classically
thought to ameliorate nonspecific fibrosis and remodeling
processes. Potentially, this could relate to the relative robust-
ness of our mice; evaluation at a later time point might have
allowed us to detect more chronic changes. Regardless,
spironolactone treatment appeared to result in less active (as
opposed to chronic) glomerulonephritis. Again, this was
observed despite the lack of difference in renal IC deposition.
However, other studies in NZB/W mice [34,35] have demon-
strated similar uncoupling between renal IC deposition and
histological damage. Thus, spironolactone appears to exert its
renoprotective effects downstream from the initial insult of IC
deposition.
To screen for potential mechanisms by which spironolactone
modulates renal damage, we studied RNA expression in kid-
neys from treated and control mice using targeted microar-
rays. We found that spironolactone treatment did not have any
significant effects on genes associated with fibrosis and extra-
cellular matrix deposition, such as different types of collagens
and metalloproteases. With the exception of the genes dis-
cussed below, we also did not detect significant differences in
renal mRNA expression of other proinflammatory cytokines,
despite diminished histopathologic activity in corresponding
tissue sections. Potentially, the cytokine signals could have
been partially diluted, because we analyzed whole kidney
homogenates, not specific regions of the kidney (as can be
obtained from laser microdissection.) Thus, lack of spironolac-
tone effect might have been reflective of the low baseline
cytokine levels detected.
A few genes potentially relevant to the pathogenesis of lupus
nephritis were downregulated by spironolactone treatment.
Spironolactone treatment decreased the renal gene expres-
sion of IFN-γ and BLyS, which correlated with clinical and his-
tologic findings of diminished SLE glomerulonephritis activity.
It has been suggested that the T-helper-1 cytokine IFN-γ plays
a critical role in active SLE glomerulonephritis. In humans,
intrarenal IFN-γ expression in biopsy specimens from SLEPage 7 of 9
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activity [36]. Treatment of NZB/W mice with anti-IFN-γ or dele-
tion of the IFN-γ receptor resulted in prolonged survival, dimin-
ished frequency and delayed onset of proteinuria, decreased
autoAb levels, and decreased histopathologic evidence of
glomerulonephritis [37-39]. BLyS, a tumor necrosis factor
homolog that stimulates B cell proliferation and maturation,
also appears to play a role early in the course of SLE and,
potentially, in lupus glomerulonephritis. Higher levels of BLyS
are detected in SLE sera and correlate with autoantibody lev-
els [40,41]. NZB/W mice have elevated serum BLyS levels
[42], and treatment of NZB/W mice with soluble BLyS recep-
tors results in delayed proteinuria, prolonged survival [42], and
decreased serum anti-dsDNA [43]. Thus, the reduction in
renal BLyS levels in spironolactone-treated mice could poten-
tially be associated with the downregulation of serum autoan-
tibodies observed by 36 weeks.
We also detected decreases in the expression of the apopto-
sis-related genes TWEAK, TRAIL, and Fas ligand. This is
intriguing, because there is a pathophysiologic basis for a role
for aldosterone in apoptosis [44], despite a paucity of studies
examining this relationship. TRAIL is upregulated on SLE T
cells [45,46] and in lupus serum [47], and has been proposed
to mediate tissue damage [46] and nephritis [48]. Urinary
TWEAK levels correlate with increased lupus activity [49]. In
addition, TWEAK induces mesangial cells to secrete proin-
flammatory chemokines [50] and induces tubular cell apopto-
sis in the presence of proinflammatory cytokines [51]; these
mechanisms are potentially relevant in the pathogenesis of
glomerulonephritis. Fas ligand is also upregulated in the
glomeruli [52] and mesangial cells [53] from human lupus
glomerulonephritis. All three apoptotic ligands are over-
expressed on lupus T cells and induce accelerated APC apop-
tosis [46]. Thus, diminishment of their levels could result in sig-
nificant immunomodulation in SLE. This would be a novel
mechanism underlying a beneficial effect of spironolactone
that must be further explored.
Conclusion
We describe the effects of aldosterone receptor blockade in a
murine model of SLE. Spironolactone is safe and well toler-
ated, and it appears to improve multiple parameters of lupus
activity when it is given early in the course of disease. It may
represent a useful therapy in combination with cytotoxic
agents, both to improve efficacy and possibly to decrease
required treatment dosages. Future studies could expand on
the current data by assessing for continued divergence
between the treatment groups at later time points, examining
the effect of spironolactone on lymphocyte function, perform-
ing more localized renal gene array analysis using laser micro-
dissection, and studying the effect of spironolactone in
combination with that of cyclophosphamide or mycophenolic
acid.
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